Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Benoit J Van Den Eynde"'
Autor:
Benoit J Van den Eynde, Maryam Ahmad, James McAuliffe, Laurine Noblecourt, Ramiro Andrei Ramirez-Valdez, Vinnycius Pereira-Almeida, Carol Sze Ki Leung, Vincent Stroobant, Amanda Wicki, Silvia Panetti, Emily Steffke, Yushu Hu, Shi Yu William Guo, Julie Lesenfants, Vineethkrishna Chandrasekar, Nathalie Vigneron
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Melanoma antigen gene (MAGE)-type antigens are promising targets for cancer immunotherapy as they are expressed in cancer cells but not in normal tissues, except for male germline cells. The mouse P1A antigen shares this MAGE-type expressi
Externí odkaz:
https://doaj.org/article/09e8625b83a644fea1c0f18984102032
Autor:
Luc Pilotte, Benoit J Van den Eynde, Jingjing Zhu, Christine Sers, Marie Solvay, Pauline Holfelder, Simon Klaessens, Vincent Stroobant, Juliette Lamy, Stefan Naulaerts, Quentin Spillier, Raphaël Frédérick, Etienne De Plaen, Christiane A Opitz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan-dioxygenase (TDO) are enzymes catabolizing the essential amino acid tryptophan into kynurenine. Expression of these enzymes is frequently observed in advanced-stage cancers and is associa
Externí odkaz:
https://doaj.org/article/8b5d6705c624408ca6c9425808c1b3f5
Autor:
Benoit J Van den Eynde, Bernard Gallez, Veronica Finisguerra, Tereza Dvorakova, Matteo Formenti, Pierre Van Meerbeeck, Lionel Mignion
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Despite their revolutionary success in cancer treatment over the last decades, immunotherapies encounter limitations in certain tumor types and patients. The efficacy of immunotherapies depends on tumor antigen-specific CD8 T-cell viabilit
Externí odkaz:
https://doaj.org/article/1d2e67c9b46f48c985ed830f6db08c69
Autor:
Federica Cappuccini, Emily Pollock, Irina Redchenko, Benoit J Van den Eynde, James McAuliffe, Hok Fung Chan, Laurine Noblecourt, Ramiro Andrei Ramirez-Valdez, Vinnycius Pereira-Almeida, Yaxuan Zhou, Adrian VS Hill, Carol Sze Ki Leung
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/76ded580fcd1416c91d0e4737e7a092b
Autor:
Marion V Guerin, Veronica Finisguerra, Benoit J Van den Eynde, Nadege Bercovici, Alain Trautmann
Publikováno v:
eLife, Vol 9 (2020)
The goal of this review is to pinpoint the specific features, including the weaknesses, of various tumor models, and to discuss the reasons why treatments that are efficient in murine tumor models often do not work in clinics. In a detailed compariso
Externí odkaz:
https://doaj.org/article/d5ab3c076e0d48109f303049d9abc1ad
Publikováno v:
Frontiers in Immunology, Vol 6 (2016)
Tryptophan is required for T lymphocyte effector functions. Its degradation is one of the mechanisms selected by tumors to resist immune destruction. Two enzymes, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 1 (IDO1), control tryp
Externí odkaz:
https://doaj.org/article/4dc58964fd6c4df9a351fbf221876e28
Autor:
Otavia L Caballero, Qi Zhao, Donata Rimoldi, Brian J Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J Van den Eynde, Lloyd J Old, Xin Lu, Jonathan Cebon, Robert L Strausberg, Andrew J Simpson
Publikováno v:
PLoS ONE, Vol 5, Iss 9, Pp 3307-3314 (2010)
BACKGROUND: Cancer/testis (CT) genes are expressed only in the germ line and certain tumors and are most frequently located on the X-chromosome (the CT-X genes). Amongst the best studied CT-X genes are those encoding several MAGE protein families. Th
Externí odkaz:
https://doaj.org/article/37fef53b5d7742bab7456b57d26a4314
Autor:
Abhishek D Garg, Lorenzo eGalluzzi, Lionel eApetoh, Thais eBaert, Raymond B Birge, Jose Manuel Bravo-San Pedro, Karine eBreckpot, David eBrough, Ricardo eChaurio, Mara eCirone, An eCoosemans, Pierre G Coulie, Dirk eDe Ruysscher, Luciana eDini, Peter ede Witte, Aleksandra M Dudek-Peric, Alberto eFaggioni, Jitka eFucikova, Udo S Gaipl, Jakub eGolab, Marie-Lise eGougeon, Michael R Hamblin, Akseli eHemminki, Martin eHerrmann, James W. Hodge, Oliver eKepp, Guido eKroemer, Dmitri V Krysko, Walter G Land, Frank eMadeo, Angelo A. Manfredi, Stephen R. Mattarollo, Christian eMaueroder, Nicolò eMerendino, Gabriele eMulthoff, Thomas ePabst, Jean-Ehrland eRicci, Chiara eRiganti, Erminia eRomano, Nicole eRufo, Mark J. Smyth, Jürgen eSonnemann, Radek eSpisek, John eStagg, Erika eVacchelli, Peter eVandenabeele, Lien eVandenberk, Benoit J Van Den Eynde, Stefaan Willy Van Gool, Francesca eVelotti, Laurence eZitvogel, Patrizia eAgostinis
Publikováno v:
Frontiers in Immunology, Vol 6 (2015)
The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens including dendritic cell-based vaccines, checkpoint-blocking ther
Externí odkaz:
https://doaj.org/article/570f706e67a046259f12244a30e66c60
Autor:
Miranda C. Lahman, Thomas M. Schmitt, Kelly G. Paulson, Nathalie Vigneron, Denise Buenrostro, Felecia D. Wagener, Valentin Voillet, Lauren Martin, Raphael Gottardo, Jason Bielas, Julie M. McElrath, Derek L. Stirewalt, Era L. Pogosova-Agadjanyan, Cecilia C. Yeung, Robert H. Pierce, Daniel N. Egan, Merav Bar, Paul C. Hendrie, Sinéad Kinsella, Aesha Vakil, Jonah Butler, Mary Chaffee, Jonathan Linton, Megan S. McAfee, Daniel S. Hunter, Marie Bleakley, Anthony Rongvaux, Benoit J. Van den Eynde, Aude G. Chapuis, Philip D. Greenberg
Publikováno v:
Sci Transl Med
Science translational medicine, Vol. 14, no.631, p. eabg8070 (2022)
Science translational medicine, Vol. 14, no.631, p. eabg8070 (2022)
Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient, who relapsed 1 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ab8910054866ad4b7f3c2247308f44
https://doi.org/10.1126/scitranslmed.abg8070
https://doi.org/10.1126/scitranslmed.abg8070
Autor:
Benoit J. Van den Eynde, Etienne Marbaix, Julie Lelotte, Nicolas van Baren, Jean-Christophe Renauld, Marie-Claire Letellier, Simon Klaessens, Marie Solvay, Aurélie Daumerie, Caroline Bouzin, Vincent Stroobant, Tereza Dvorakova, Delia Hoffmann
Supplementary figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e5b11eee0feb91d4c6a59bc085457d
https://doi.org/10.1158/2326-6066.22543315.v1
https://doi.org/10.1158/2326-6066.22543315.v1